Skip to content

Lobbying by Best Medicines Coalition: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Client of a consultant lobbyist

Best Medicines Coalition

Meetings this Parliament
0
With MPs
0
Since Nov 2021
0
Active registrations
1

Bills they've lobbied on

Named in their own descriptions of meetings or of their registration. Their words are quoted below each bill.

Registrations in effect

Consultant In effect since Jul 13, 2026

Consultant Jay Strauss

Consultant lobbyists

  • Jay Strauss Former public office holder

    Formerly Communications Analyst, Liberal Caucus Research Bureau, House of Commons (2006–2009)

    Formerly Electronic Information Director, Press Office, Prime Minister's Office (2003–2006)

    Formerly Summer student, Human Resources (seconded part of the summer to the Minister's Office), Health Canada (2002–2002)

    Formerly Summer student, Minister's Office, Veterans Affairs Canada (2001–2001)

Institutions they may lobby: Employment and Social Development Canada (ESDC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Office of the Auditor General of Canada (OAG), Office of the Public Sector Integrity Commissioner (PSIC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Safety Canada (PS), Public Services and Procurement Canada (PSPC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)

What they're lobbying on (16)
  • Support input into the consultation on modernizing the framework for clinical trials.
  • Support input regarding the Pharmaceutical and Life Sciences Sector Task Force.
  • Support input regarding Canada’s pharmaceutical sovereignty.
  • Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.
  • Support input into the consultation on draft guidance on decentralized clinical trials.
  • Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.
  • Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.
  • Recommend the creation of a Patient Ombudsman.
  • Recommend the creation of a Chief Patient Officer.
  • Provide input on pharmacare.
  • Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.
  • Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.
  • Provide input on a national strategy for drugs for rare diseases.
  • Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.
  • Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.
  • Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.

Registration 926360-357616-71. Look it up in the official Registry

Reported meetings

No meetings reported since November 2021.

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.